Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00236275
Status:
COMPLETED
Last Update Posted:
2011-05-02
First Post:
2005-10-11
Brief Title:
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Predict and follow thanks to imaging the response to neoadjuvant chemotherapy in locally advanced breast carcinoma Hypothesis FLT-18FPET will be a predictor superior to both FDG-18F PET and MRI
Detailed Description:
PETCT with FDG-18F and FLT-18F and MRI are performed at the initial staging 3 times during sequential adjuvant chemotherapy and prior to surgery aiming to find the most efficient modality to predict the response to neoadjuvant chemotherapy of the primary breast cancer and its possible lymph node metastases Post-surgical histology and a 6 month follow-up to detect occult metastases will constitute the standard of truth for determination and comparison of diagnostic performances
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None